← Trials/Trial dossier/NCT06351748

SCHOLAR

Completed

Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)

Lead sponsor

Novo Nordisk A/S

Asset

Semaglutide

GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

34,238

actual

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoints

•HbA1c, change•HbA1c <7.0% achievement

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06351748

Org study IDNN9535-7877

Secondary IDU1111-1296-3151World Health Organization (WHO)

Timeline

Milestones

Study start2024-01-02actual

Primary completion2024-03-29actual

Study completion2024-03-29actual

Study first posted2024-04-08actual

Last update posted2025-04-16actual

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Sampling methodProbability sample

Study population text

Participants diagnosed with T2DM who initiated semaglutide OW for the first time during the patient identification period.

Inclusion criteria

•Male or female participants aged greater than or equal to (≥) 18 years on index date

•Participants with diagnosis of T2DM prior to or on index date

•Participants with initiation of semaglutide OW for the first time within the identification period

Exclusion criteria

•Participants with diagnosis of type 1 diabetes prior to or on index date

•Participants who were pregnant within 36 months prior to or on index date

•Participants who participated in any clinical trials within 36 months prior to or on index date which could be identified from medical records

Endpoints (12)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Other (unclassified)

Weight & body composition

2 endpoints

Secondary/protocol endpoint

Change in body weight

Time frame:From baseline (3 months prior to or on the index date) to 12 months

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Change in body weight

Time frame:From baseline (3 months prior to or on the index date) to 6 months

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

7 endpoints

Primary/protocol endpoint

Change in Haemoglobin A1c (HbA1c) level

Time frame:From baseline (3 months prior to or on the index date) to 6 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Primary/protocol endpoint

Change in HbA1c level

Time frame:From baseline (3 months prior to or on the index date) to 6 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Primary/protocol endpoint

Proportion of participants achieving HbA1c less than (<) 7.0%

Time frame:At 6 months

HbA1c <7.0% achievement

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in HbA1c level

Time frame:From baseline (3 months prior to or on the index date) to 12 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in HbA1c level

Time frame:From baseline (3 months prior to or on the index date) to 12 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Proportion of participants achieving HbA1c <7.0%

Time frame:At 12 months

HbA1c <7.0% achievement

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Proportion of participants with different antidiabetic medications

Time frame:At baseline (3 months prior to or on the index date)

descriptive

Other (unclassified)

3 endpoints

Secondary/protocol endpoint/low confidence

Description of participants with different demographic characteristics

Time frame:At baseline (12 months prior to or on the index date)

descriptive

Secondary/protocol endpoint/low confidence

Description of participants with different clinical characteristics

Time frame:At baseline (36 months prior to or on the index date)

descriptive

Secondary/protocol endpoint/low confidence

Proportion of participants with different non-antidiabetic medications

Time frame:At baseline (3 months prior to or on the index date)

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Real-World Cohort Study of Semaglutide in Adults with Type 2 Diabetes Using an Electronic Health Records Database in Tianjin, China.
Diabetes therapy : research, treatment and education of diabetes and related disorders2026 Apr (month)PMID41848818doi:10.1007/s13300-026-01848-6via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.